:breakthroughs and trends in cell culture technology
نام نخستين پديدآور
/ edited by Uwe Marx and Volker Sandig
وضعیت نشر و پخش و غیره
محل نشرو پخش و غیره
Weinheim
نام ناشر، پخش کننده و غيره
: Wiley-VCH,
تاریخ نشرو بخش و غیره
, c2007.
مشخصات ظاهری
نام خاص و کميت اثر
xix, 298 p. ill. 25 cm.
یادداشتهای مربوط به نشر، بخش و غیره
متن يادداشت
e
یادداشتهای مربوط به کتابنامه ، واژه نامه و نمایه های داخل اثر
متن يادداشت
ng
متن يادداشت
Includes bibliographical references and index.
یادداشتهای مربوط به مندرجات
متن يادداشت
Intelligent biomatrices and engineered tissue constructs : in-vitro models for drug discovery and toxicity testing / Philip Lazarovici, Mengyan Li, Anat Perets, Mark J. Mondrinos, Shimon Lecht, Christopher D. Koharski, Paul R. Bidez III, Christine M. Finck, Peter I. Lelkes -- An overview on bioreactor design, prototyping and process control for reproducible three-dimensional tissue culture / Ralf Portner, Christoph Giese -- An overview on bioelectronic and biosensoric microstructures supporting high-content screening in cell cultures / Andrea A. Robitzki, Andree Rothermel -- Novel in-vitro exposure techniques for toxicity testing and biomonitoring of airborne contaminants / Amanda Hayes, Shahnaz Bakand, Chris Winder -- Drug screening using cell lines : cell supply, high-throughput and high-content assays / Christa Burger, Oliver Poschke, Mirek R. Jurzak -- Cell lines and primary tissues for in-vitro evaluation of vaccine efficacy / Anthony Meager -- Designer cells derived from primary tissue and designed cell lines as a sustainable cell source for drug discovery and safety assessment / Volker Sandig, Ingo Jordan -- How human embryonic stem cell research can impact in-vitro drug screening technologies of the future / Andre Schrattenholz, Martina Klemm -- Availability, standardization and safety of human cells and tissues for drug screening and testing / Glyn N. Stacey, Thomas Hartung -- Ethical environment and scientific rationale towards in-vitro alternatives to animal testing: where are we going? / Horst Spielmann -- How drug development of the 21st century could benefit from human micro-organoid in-vitro technologies.